| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6930129 | JANSSEN PHARMS | Methods and devices for providing prolonged drug therapy |
Jul, 2017
(6 years ago) | |
| US6919373 | JANSSEN PHARMS | Methods and devices for providing prolonged drug therapy |
Jul, 2017
(6 years ago) | |
| US8163798 | JANSSEN PHARMS | Methods and devices for providing prolonged drug therapy |
Jul, 2017
(6 years ago) | |
| US9144549 | JANSSEN PHARMS | Methods and devices for providing prolonged drug therapy |
Jul, 2017
(6 years ago) | |
| US9000038 | JANSSEN PHARMS | Methods and devices for providing prolonged drug therapy |
Jul, 2017
(6 years ago) | |
| US9029416 | JANSSEN PHARMS | Methods and devices for providing prolonged drug therapy |
Jul, 2017
(6 years ago) | |
| US8629179 | JANSSEN PHARMS | Methods and devices for providing prolonged drug therapy |
Jul, 2017
(6 years ago) | |
|
US6930129 (Pediatric) | JANSSEN PHARMS | Methods and devices for providing prolonged drug therapy |
Jan, 2018
(6 years ago) | |
|
US6919373 (Pediatric) | JANSSEN PHARMS | Methods and devices for providing prolonged drug therapy |
Jan, 2018
(6 years ago) | |
|
US8163798 (Pediatric) | JANSSEN PHARMS | Methods and devices for providing prolonged drug therapy |
Jan, 2018
(6 years ago) | |
|
US8629179 (Pediatric) | JANSSEN PHARMS | Methods and devices for providing prolonged drug therapy |
Jan, 2018
(6 years ago) | |
|
US9000038 (Pediatric) | JANSSEN PHARMS | Methods and devices for providing prolonged drug therapy |
Jan, 2018
(6 years ago) | |
Concerta is owned by Janssen Pharms.
Concerta contains Methylphenidate Hydrochloride.
Concerta has a total of 12 drug patents out of which 12 drug patents have expired.
Expired drug patents of Concerta are:
- US6930129
- US6919373
- US8163798
- US9144549
- US9000038
- US9029416
- US8629179
- US6930129*PED
- US6919373*PED
- US8163798*PED
- US8629179*PED
- US9000038*PED
Concerta was authorised for market use on 01 August, 2000.
Concerta is available in tablet, extended release;oral dosage forms.
Concerta can be used as for claims 1-3,6-13,16-24 and 26-32: method of treating adhd, method of treating adhd in children 6 years of age and older and adolescents, method of treating adhd.
The generics of Concerta are possible to be released after 31 January, 2018.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-88) | Nov 04, 2012 |
Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient
Market Authorisation Date: 01 August, 2000
Treatment: Method of treating adhd; For claims 1-3,6-13,16-24 and 26-32: method of treating adhd; Method of treating adhd in children 6 years of age and older and adolescents
Dosage: TABLET, EXTENDED RELEASE;ORAL
CONCERTA family patents
